Patient-specific renal cell carcinoma tumor-associated antigens and dinitrophenyl-modified neoantigens presented by major histocompatibility complex (RCC TAA/DNP-neoantigen complex)

This target refers to the unique profile of antigens presented on the surface of a patient's own renal cell carcinoma (RCC) cells, specifically those modified by the hapten dinitrophenyl (DNP). It encompasses both endogenous tumor-associated antigens (TAAs) and DNP-induced neoantigens that are presented to the immune system via the Major Histocompatibility Complex (MHC) (Berd et al., 1991). In a therapeutic context, these antigens are the focus of personalized immunotherapy, where a patient's tumor cells are harvested, chemically modified with DNP, and re-administered as a vaccine (Urosevic et al., 2003). The presence of the DNP hapten serves to increase the visibility of the tumor cells to the immune system, effectively breaking the body's natural tolerance to the cancer (ClinicalTrials.gov, NCT00003155). This process triggers the activation of cytotoxic T-lymphocytes that can recognize and destroy RCC cells expressing these specific antigen complexes. Consequently, the target is central to the development of autologous cell-based vaccines designed to treat advanced or metastatic renal cell carcinoma.

Other names

DNP-modified autologous RCC antigensDNP-RCC neoantigensHapten-modified tumor antigensDNP-modified tumor-associated antigensK-Vax target antigens

The vaccine utilizes dinitrophenyl (DNP) as a hapten to modify autologous tumor cells, thereby increasing the immunogenicity of patient-specific tumor-associated antigens. This modification helps bypass immunological tolerance, stimulating a cytotoxic T-lymphocyte response against the patient's native renal cell carcinoma cells (Berd et al., 1991; Urosevic et al., 2003).